Acceleron Pharma Inc EBITDA margin
Was ist das EBITDA margin von Acceleron Pharma Inc?
EBITDA margin von Acceleron Pharma Inc ist -222.82%
Was ist die Definition von EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acceleron Pharma Inc
Was macht Acceleron Pharma Inc?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Unternehmen mit ebitda margin ähnlich Acceleron Pharma Inc
- Star Royalties hat EBITDA margin von -224.44%
- General Assembly hat EBITDA margin von -223.97%
- Blockmint Technologies hat EBITDA margin von -223.45%
- Hydrocarbon Dynamics hat EBITDA margin von -223.22%
- Vast Resources plc hat EBITDA margin von -223.12%
- uniQure N.V hat EBITDA margin von -223.09%
- Acceleron Pharma Inc hat EBITDA margin von -222.82%
- Greenway Mining hat EBITDA margin von -222.31%
- Qudian Inc hat EBITDA margin von -221.61%
- Lumos Diagnostics hat EBITDA margin von -220.54%
- Gossamer Bio hat EBITDA margin von -220.43%
- AML3D hat EBITDA margin von -220.30%
- Jayshree Chemicals hat EBITDA margin von -219.42%